Company attributes
Other attributes
ProMIS Neurosciences is a development stage biotechnology company that focuses on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in Alzheimer’s disease, amyotrophic lateral sclerosis and Parkinson’s disease.
Its scientific foundation is based on the growing consensus that toxic oligomers are vital drivers of neurodegenerative diseases. The company is based around the leading science of Dr. Neil Cashman, Professor of Medicine at the University of British Columbia, Neuroscientist at the Brain Research Center, and Academic Director of the Vancouver Coastal Hospital ALS Center.
ProMIS Neurosciences uses two proprietary computational discovery technologies, ProMIS™ and Collective Coordinates for predicting novel targets that are known as Disease Specific Epitopes (DSEs) on the molecular surface of toxic oligomers.
ProMIS Neurosciences has a patent estate with over 75 patents issued or pending for disease specific epitopes and monoclonal antibodies targeting toxic oligomers implicated in the development of Alzheimer’s disease (oligomers of amyloid beta), ALS (oligomers of SOD1, TDP43) and Parkinson’s disease (oligomers of alpha synuclein).
